Enliven Therapeutics's market cap is currently $1.19B. The company's EPS TTM is $-0.49; its P/E ratio is ―; Enliven Therapeutics is scheduled to report earnings on August 13, 2025, and the estimated EPS forecast is $-0.43. See an overview of income statement, balance sheet, and cash flow financials.
